GlassScriptPhysician profile
Amna A Salhin
NPI 1790741726
$10,792.70
in general payments reported to CMS, 2019-2025
42 companies · $2,436 in 2025
The $2,436 reported for 2025 was more than what 80% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
See the full distribution for Endocrinology, Diabetes & Metabolism
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $732 · 2020: $1,832 · 2021: $553 · 2022: $1,313 · 2023: $1,853 · 2024: $2,074 · 2025: $2,436.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,359 · Education: $4.21.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,358.72 |
| Education | $4.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Tandem Diabetes Care, INC. | $1,375.00 | 2019-2020 | |
| Lilly USA, LLC | $698.98 | 2021-2025 | Jardiance, Mounjaro, Zepbound |
| Novo Nordisk INC | $627.69 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Boehringer Ingelheim Pharmaceuticals, INC. | $569.51 | 2020-2025 | Jardiance, Synjardy, Tradjenta |
| Abbott Laboratories | $569.32 | 2020-2025 | Freestyle Libre 3 |
| Mannkind Corporation | $522.10 | 2022-2025 | Afrezza |
| Antares Pharma, INC. | $488.27 | 2019-2022 | |
| Sanofi-Aventis U.S. LLC | $470.90 | 2022-2025 | |
| Abbvie INC. | $425.18 | 2019-2025 | Synthroid, Ubrelvy |
| Amgen INC. | $384.12 | 2023-2025 | Repatha, Evenity, Prolia |
| Medtronic, INC. | $376.84 | 2021-2025 | Minimed 780g, Intellis Adaptivestim, Inceptiv |
| Corcept Therapeutics | $339.90 | 2020-2025 | Korlym |
| Cequr Corporation | $325.54 | 2022-2025 | Cequr Simplicity |
| Novartis Pharmaceuticals Corporation | $324.08 | 2021-2025 | |
| Ascensia Diabetes Care US INC. | $317.37 | 2023-2025 |
Show all 42 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Xeris Pharmaceuticals, INC. | $307.61 | 2020-2025 | Gvoke Hypopen |
| Dexcom, INC. | $292.32 | 2021-2025 | Dexcom G6 Transmitter |
| Recordati_rare_diseases_inc. | $233.25 | 2023-2025 | Isturisa, Signifor Lar |
| Kyowa Kirin, INC. | $221.99 | 2023-2025 | Crysvita |
| Radius Health, INC. | $210.84 | 2020-2025 | Tymlos |
| Sequel Med Tech, LLC | $206.43 | 2025 | Twiist |
| Astrazeneca Pharmaceuticals LP | $183.81 | 2020-2023 | Farxiga |
| Medtronic Minimed, INC. | $164.74 | 2019-2020 | |
| Nevro Corp. | $136.15 | 2021-2023 | Senza |
| Zealand Pharma US, INC. | $132.79 | 2020-2021 | |
| Neurocrine Biosciences, INC. | $117.32 | 2024-2025 | |
| Soleno Therapeutics, INC. | $107.81 | 2025 | Vykat Xr |
| Insulet Corporation | $102.15 | 2019-2025 | Omnipod |
| Bayer Healthcare Pharmaceuticals INC. | $95.51 | 2022-2025 | |
| Merck Sharp & Dohme LLC | $80.67 | 2020-2022 | |
| Madrigal Pharmaceuticals | $73.00 | 2025 | Rezdiffra |
| Organogenesis INC. | $67.70 | 2022-2023 | Puraply |
| Janssen Pharmaceuticals, INC | $53.33 | 2019-2020 | |
| Lifescan, INC. | $42.64 | 2021-2022 | |
| Rhythm Pharmaceuticals, INC. | $32.30 | 2025 | Imcivree |
| Almatica Pharma LLC | $21.96 | 2024 | Teriparatide |
| Ultragenyx Pharmaceutical INC. | $21.65 | 2022 | |
| Amarin Pharma, INC. | $17.30 | 2020 | |
| Averitas Pharma INC. | $17.16 | 2025 | Qutenza |
| Horizon Therapeutics Plc | $16.64 | 2020 | |
| Pfizer INC. | $14.63 | 2025 | |
| Beta Bionics, INC. | $6.20 | 2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Inset, Ilet Insulin Infusion Kit Contact Detach |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amna Salhin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.